Axonics® Granted Seven New U.S. Patents Related to its Implantable Sacral Neuromodulation Technology - Gilde Healthcare

Axonics® Granted Seven New U.S. Patents Related to its Implantable Sacral Neuromodulation Technology

December 4, 2017

Irvine, CA – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of bladder and bowel dysfunction, announced today that the United States Patent and Trademark Office has granted Axonics seven new U.S. patents along with numerous foreign counterparts relating to its implantable sacral neuromodulation technology.

The most recently issued patents granted during the second half of 2017 range in subject matter and include coverage of the Company’s external pulse generator, implantable lead design and internal system electronics. The issued U.S. patents are: 9,802,038; 9,802,051; 9,700,731; 9,770,596; 9,728,981; 9,789,325; 9,780,596.

“The continued growth of the Axonics patent portfolio further demonstrates the level of innovation and commitment to technical excellence behind the clinical and business milestones that the Company has reported in 2017,” said Raymond W. Cohen, Axonics Chief Executive Officer. “With these seven new U.S. patents, we presently have more than 100 granted and 80 pending patent applications in our portfolio in various jurisdictions around the world.”

The Axonics patent portfolio represents technology internally developed by Axonics and technology developed under license from the Alfred Mann Foundation.

During 2016, the Axonics r-SNM System® received European CE Mark approval and Health Canada approval for the treatment of overactive bladder, urinary retention, and fecal incontinence. Recently, the U.S. FDA granted Axonics an IDE to conduct a pivotal study geared toward gaining marketing approval in the United States.

First Enrolment in the ProVIDE Clinical Study for BPH Treatment

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor’s office, today announced the commencement of the ProVIDE pivotal clinical trial to evaluate the...
June 10, 2022

Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiveness

Big Health has become the first digital therapeutics company to receive guidance from the National Institute for Health and Care Excellence (NICE), which has recommended Sleepio as a cost-saving option for treating insomnia in a move that heralds...
May 20, 2022

Gilde Healthcare portfolio company Synexa Life Sciences acquires Finnish CRO Syrinx Bioanalytics to expand bioanalysis capabilities in clinical drug development

Gilde Healthcare portfolio company Synexa Life Sciences BV, a global leader in specialist biomarker and bioanalysis research services, has today announced that it has acquired Syrinx Bioanalytics, a bioanalytical CRO based in Turku, Finland. The move...
May 19, 2022